AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca is conducting a Phase III clinical study titled ‘Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen.’ The study aims to assess the efficacy of tozorakimab, an investigational drug, in preventing death or the need for invasive mechanical ventilation or extracorporeal membrane oxygenation in hospitalized patients with viral lung infections.
The intervention being tested is tozorakimab, administered as a single intravenous dose. Tozorakimab is designed to be an add-on treatment to the standard of care for patients requiring supplemental oxygen due to viral lung infections.
The study design is interventional, with a randomized, parallel-group model. It employs triple masking, meaning that participants, care providers, and investigators are blinded to the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on December 13, 2022, and is currently recruiting participants. The last update was submitted on June 30, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and potential results.
This clinical update could influence AstraZeneca’s stock performance by bolstering investor confidence, especially if the results are favorable. The study’s progress is significant in the context of the pharmaceutical industry’s ongoing efforts to address viral lung infections, potentially impacting competitor strategies as well.
The study is ongoing, with further details available on the ClinicalTrials portal.